Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.20
Bid: 44.10
Ask: 45.90
Change: -0.50 (-1.10%)
Spread: 1.80 (4.082%)
Open: 43.00
High: 43.20
Low: 43.00
Prev. Close: 45.50
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

8 Sep 2017 07:00

RNS Number : 2016Q
Benchmark Holdings PLC
08 September 2017
 

 

RNS

 

Information within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014.

 

 

Benchmark Holdings plc("Benchmark" or the "Company")

 

Trading Update

 

Benchmark, the aquaculture biotechnology and food chain sustainability business, issues the following trading update for the year ending 30 September 2017.

 

Overall performance across the Group has been good, with strong growth in sales in the Breeding and Genetics Division, and improved market conditions for the Advanced Animal Nutrition Division in the second half.

 

The Animal Health Division continues to manage a valuable portfolio of products in development, and the board remains confident of delivering the Company's medium and long term strategy of an increasingly diversified portfolio of both products and services. The Group is approaching the launch of commercial field trials of its innovative new sea lice treatment, and is closely engaged with major salmon producers, with the bulk of the equipment and licences for the trials now in place. Management are confident that commercial field trials will start before the end of December 2017, although the exact timing of these trials remains unclear and they are unlikely to commence before the end of September. Consequently, contributions attributable to this new product are unlikely to be recognised in FY17.

 

As a result, the Company is providing guidance that it expects Group revenues to be in line with market expectations, and adjusted EBITDA to be in the range £8.7m to £9.3m, for the full year.

 

 

 

 

 

-ENDS-

 

Benchmark Holdings plc

Tel: 020 7920 3150

Malcolm Pye, CEO

Rachel Aninakwah, Communications

Numis

Tel: 020 7260 1000

Michael Meade / Freddie Barnfield (NOMAD)

James Black (Corporate Broking)

Tavistock

Tel: 020 7920 3150

Niall Walsh / Simon Hudson

 

 

Notes to Editors:

Benchmark challenges the status quo in aquaculture, agriculture and animal healthcare.

 

Since 2000, Benchmark has consistently worked to build a platform to serve its customers, helping farmers to take control of their biological environment through the combination of genetics, nutrition, health and knowledge services. Through its in-depth knowledge of animal biology Benchmark is able to tackle the key issues in the aquaculture, livestock and companion animal sectors.

 

The Company has proven distribution capabilities in high growth markets and operates internationally with R&D facilities, commercial farms, diagnostic laboratories, manufacturing sites, production facilities and commercial offices across 27 countries in five continents. As at 30 June 2017, Benchmark employed 951 people. 

 

For further information on Benchmark please visit www.benchmarkplc.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTOKFDQPBKKACK
Date   Source Headline
31st Mar 20237:00 amRNSTotal Voting Rights
21st Mar 20235:33 pmRNSShare Premium Reduction
21st Mar 20237:00 amRNSBlock Listing Six Monthly Return
17th Mar 20236:09 pmRNSHolding(s) in Company
2nd Mar 202311:12 amRNSDirector Dealings
28th Feb 20239:00 amRNSTotal Voting Rights
28th Feb 20237:00 amRNSQ1 Results
17th Feb 20237:00 amRNSAcquisition of remaining minority interest
16th Feb 20236:03 pmRNSResult of AGM
14th Feb 202311:45 amRNSNotice of Q1 Results
31st Jan 20237:00 amRNSTotal Voting Rights
27th Jan 20234:40 pmRNSSecond Price Monitoring Extn
27th Jan 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20234:40 pmRNSSecond Price Monitoring Extn
17th Jan 20234:35 pmRNSPrice Monitoring Extension
11th Jan 20238:00 amRNSPosting of Notice of AGM
30th Dec 20227:00 amRNSTotal Voting Rights
16th Dec 20229:58 amRNSHolding(s) in Company
15th Dec 20227:00 amRNSFirst Day of Trading on Euronext Growth Oslo
14th Dec 20229:15 amRNSCompletion of private placement & retail offering
13th Dec 20224:30 pmRNSSufficient number of shares in VPS
6th Dec 20226:21 pmRNSSuccessful private placement and retail offering
6th Dec 20227:00 amRNSLast day of bookbuilding and application period
1st Dec 20223:36 pmRNSPublication of Annual Report and Notice of AGM
1st Dec 202210:58 amRNSStatus of bookbuilding
1st Dec 20227:00 amRNSProspectus & Commencement of Bookbuilding Period
30th Nov 202210:00 amRNSTotal Voting Rights
30th Nov 20227:01 amRNSPrivate Placing & Retail Offering
30th Nov 20227:00 amRNSQ4 Results
30th Nov 20227:00 amRNSFull Year Results
25th Nov 20227:00 amRNSNotice of Results
14th Nov 20224:40 pmRNSSecond Price Monitoring Extn
14th Nov 20224:35 pmRNSPrice Monitoring Extension
14th Nov 20224:35 pmRNSChange of Registered Office
31st Oct 20227:00 amRNSTotal Voting Rights
24th Oct 20227:00 amRNSTrading Update
19th Oct 20227:00 amRNSHolding(s) in Company
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20224:35 pmRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSTotal Voting Rights
21st Sep 20227:00 amRNSBlock listing Six Monthly Return
20th Sep 20227:00 amRNSBenchmark hosts Capital Markets Day today
16th Sep 20227:00 amRNSRefinances the Company's existing debt
15th Sep 20224:35 pmRNSPrice Monitoring Extension
6th Sep 20227:00 amRNSFixed Income Investor Meetings
31st Aug 20227:00 amRNSTotal Voting Rights
25th Aug 20227:00 amRNSQ3 Results
1st Aug 20227:00 amRNSNotice of Q3 Results
29th Jul 20227:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.